Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 9, 2009, Pages 1407-1416

  Bartolomei, Mirco ^a   Bodei, Lisa ^a   De Cicco, Concetta ^a   Grana, Chiara Maria ^a   Cremonesi, Marta ^a   Botteri, Edoardo ^a   Baio, Silvia Melania ^a   Aricò, Demetrio ^a   Sansovini, Maddalena ^b   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

90Y DOTATOC; Meningioma; Octreotide; Peptide receptor radionuclide therapy; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE Y 90; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MENINGIOMA; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 68949212314     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1115-z     Document Type: Article

References (50)

1. Black P. Meningiomas. In: Black P, Loeffler JS, editors. Cancer of the nervous system. Oxford UK: Blackwell Science; 1997. p. 349-62.
2. Russel D, Rubinstein L. Tumours of the meninges and related tissues. In: Russel D, Rubinstein L, editors. Pathology of tumours of the nervous system. Baltimore: Williams and Wilkins; 1989. p. 449-532.
3. Rachlin J, Rosenblum M. Etiology and biology of meningiomas. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 22-37.
4. Drake J, Hoffman H. Meningiomas in children. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 145-52.
5. G Butti R Assietti R Casalone P Paoletti 1989 Multiple meningiomas: a clinical, surgical and cytogenetic analysis Surg Neurol 31 255 260
6. B Modan D Baidatz H Mart R Steinitz SG Levin 1974 Radiation-induced head and neck tumours Lancet 1 277 279
7. C Balasubramaniam D Armstrong W Cheek J Laurent 1988 Postradiation meningiomas in a child Pediatr Neurosci 14 3 319 323
8. J Mark G Levan F Mitelman 1972 Identification by fluorescence of the G chromosome lost in human meningiomas Hereditas 71 163 168
9. H Zankl KD Zang 1972 Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique Humangenetik 14 2 167 169
10. P Kleihues DN Louis BW Scheithauer LB Rorke G Reifenberger PC Burger, et al 2002 The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 3 215 229
11. D Simpson 1957 The recurrence of intracranial meningiomas after surgical treatment J Neurol Neurosurg Psychiatry 20 22 39
12. RO Marimanoff DE Dosoretz RM Linggood RG Ojemann RL Martuzza 1985 Meningioma: analysis of recurrence and progression after neurosurgical resection J Neurosurg 62 18 24
13. J Jaaskelainen M Haltia A Servo 1986 Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome Surg Neurol 25 233 242
14. BW Taylor Jr RB Marcus Jr WA Friedman WE Ballinger Jr RR Million 1988 The meningioma controversy: postoperative radiation therapy Int J Radiat Oncol Biol Phys 15 299 304
15. KS Condra JM Buatti WM Mendenhall WA Friedman RB Marcus Jr AL Rhoton 1997 Benign meningiomas: primary treatment selection affects survival Int J Radiat Oncol Biol Phys 39 2 427 436
16. JB Mesic GE Hanks RL Doggett 1986 The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas Am J Clin Oncol 9 4 337 340
17. TW Dziuk S Woo EB Butler J Thornby R Grossman WS Dennis, et al 1998 Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy J Neurooncol 37 2 177 188
18. RC Chan GB Thompson 1984 Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases J Neurosurg 60 52 60
19. BJ Goldsmith WM Wara CB Wilson DA Larson 1994 Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990 J Neurosurg 80 195 201
20. PY Wen J Drappatz 2006 Novel therapies for meningiomas Expert Rev Neurother 6 10 1447 1464
21. S Pravdenkova O Al-Mefty J Sawyer M Husain 2006 Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas J Neurosurg 105 2 163 173
22. PM Black 1997 Hormones, radiosurgery and virtual reality: new aspects of meningioma management Can J Neurol Sci 24 4 302 306
23. JC Reubi EP Krenning SW Lamberts L Kvols 1993 In vitro detection of receptors in human tumours Digestion 54 Suppl 1 76 83
24. M De Jong R Valkema F Jamar LK Kvols DJ Kwekkeboom WA Breeman, et al 2002 Somatostatin receptor-targeted radionuclide therapy of tumours: preclinical and clinical findings Semin Nucl Med 32 2 133 140
25. JC Reubi R Maurer JG Klijn SZ Stefanko JA Foekens G Blaauw, et al 1986 High incidence of somatostatin receptors in human meningiomas: biochemical characterization J Clin Endocrinol Metab 63 433 438
26. WW de Herder DJ Kwekkeboom R Valkema RA Feelders MO van Aken SW Lamberts, et al 2005 Neuroendocrine tumors and somatostatin: imaging techniques J Endocrinol Invest 28 11 Suppl International 132 136
27. M van Essen EP Krenning M De Jong R Valkema DJ Kwekkeboom 2007 Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours Acta Oncol 46 6 723 734
28. JP Esser EP Krenning JJ Teunissen PP Kooij AL van Gameren WH Bakker, et al 2006 Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33 11 1346 1351
29. DJ Kwekkeboom JJ Teunissen WH Bakker PP Kooij WW de Herder RA Feelders, et al 2005 Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors J Clin Oncol 23 12 2754 2762
30. L Bodei M Cremonesi C Grana P Rocca M Bartolomei M Chinol, et al 2004 Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 31 7 1038 1046
31. G Paganelli L Bodei D Handkiewicz Junak P Rocca S Papi M Lopera Sierra, et al 2002 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies Biopolymers 66 6 393 398
32. G Paganelli S Zoboli M Cremonesi L Bodei M Ferrari C Grana, et al 2001 Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide Eur J Nucl Med 28 4 426 434
33. L Bodei D Handkiewicz-Junak C Grana C Mazzetta P Rocca M Bartolomei, et al 2004 Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas Cancer Biother Radiopharm 19 1 65 71
34. M Chinol L Bodei M Cremonesi G Paganelli 2002 Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of Oncology Group Semin Nucl Med 32 2 141 147
35. L Bodei M Cremonesi S Zoboli C Grana M Bartolomei P Rocca, et al 2003 Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study Eur J Nucl Med Mol Imaging 30 2 207 216
36. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization Offset Publication; 1979. p. 48.
37. S Green GR Weiss 1992 Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 10 239 253
38. SM Grunberg MH Weiss IM Spitz J Ahmadi A Sadun CA Russell, et al 1991 Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone J Neurosurg 74 6 861 866
39. Grumberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, et al. Phase III double-blind randomized placebo controlled study of mifepristone (RU) for the treatment of unresectable meningioma. ASCO 2001 Proceedings 20:56a.
40. S Klutmann KH Bohuslavizki W Brenner A Behnke N Tietje S Kröger, et al 1998 Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma J Nucl Med 39 1913 1917
41. M Henze A Dimitrakopoulou-Strauss S Milker-Zabel J Schuhmacher LG Strauss J Doll, et al 2005 Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas J Nucl Med 46 5 763 769
42. E Gay JP Vuillez O Palombi PY Brard P Bessou JG Passagia 2005 Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas Neurosurgery 57 1 Suppl 107 113
43. MC Chamberlain MJ Glantz CE Fadul 2007 Recurrent meningioma: salvage therapy with long-acting somatostatin analogue Neurology 69 10 969 973
44. JW Koper R Markstein C Kohler DJ Kwekkeboon CJ Avezaat SW Lamberts, et al 1992 Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth J Clin Endocrinol Metab 74 3 543 547
45. KW Ko DH Nam DS Kong JI Lee K Park JH Kim 2007 Relationship between malignant subtypes of meningioma and clinical outcome J Clin Neurosci 14 8 747 753
46. A Modha PH Gutin 2005 Diagnosis and treatment of atypical and anaplastic meningiomas: a review Neurosurgery 57 3 538 550
47. DM Ho CY Hsu LT Ting H Chiang 2002 Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma Cancer 94 5 1538 1547
48. B Brans L Bodei F Giammarile O Linden M Luster WJ Oyen J Tennvall 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" Eur J Nucl Med Mol Imaging 34 5 772 786
49. M Cremonesi M Ferrari L Bodei G Tosi G Paganelli 2006 Dosimetry in peptide radionuclide receptor therapy: a review J Nucl Med 47 9 1467 1475
50. M van Essen EP Krenning PP Kooij WH Bakker RA Feelders WW de Herder, et al 2006 Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma J Nucl Med 47 10 1599 1606